Contact Us
Contact Us
Contact Us

Investors

Welcome to our Investor page. Here you will find information on the latest ASX announcements, investor presentations and other shareholder information on Race Oncology.

Race Oncology

Race Oncology is a specialty pharmaceutical company focused on rediscovering and rescuing life-saving drugs that can deliver early commercial milestones. Race Oncology’s first asset is Bisantrene, a small molecule Chemotherapy drug that has been evaluated clinically for Acute Myeloid Leukaemia (AML).

ASX Announcements



DateTitle
06/07/2020Appendix 2ADownload
06/07/2020Cleansing NoticeDownload
01/07/2020Appendix 2ADownload
01/07/2020Cleansing NoticeDownload
29/06/2020Appendix 3Y-Phillip LynchDownload
29/06/2020Cancer Cell Journal PublicationDownload
22/06/2020Appendix 2ADownload
22/06/2020Cleansing NoticeDownload
19/06/2020Notification of Lapse of Unlisted OptionsDownload
19/06/2020Webinar transcript and presentation updateDownload
1  2  3  4  5  6  

ASX: RAC

Price

Latest News

Read All Stories

Don't miss important updates

Get the latest news & announcement and stay up-to-date.

© 2020 Race Oncology. Website By Multiplier